Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFWOTCMKTS:FFNTFNASDAQ:LBPSWOTCMKTS:RGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.01-1.2%$0.01$0.00▼$0.04N/AN/A98,670 shs32,440 shsFFNTF4Front Ventures$0.00+100.0%$0.00$0.00▼$0.11N/AN/A1.38 million shs919,024 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/ARGRXRegeneRx Biopharmaceuticals$0.00$0.00$0.00▼$0.07N/A3.028 shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences-1.19%+1.22%+10.67%-1.19%-13.54%FFNTF4Front Ventures+100.00%-60.00%-71.43%-98.86%-99.80%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%RGRXRegeneRx Biopharmaceuticals0.00%0.00%0.00%-85.71%-85.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/ARGRXRegeneRx Biopharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/ARGRXRegeneRx Biopharmaceuticals$80K0.00N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ARGRXRegeneRx Biopharmaceuticals-$1.73MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/ARGRXRegeneRx BiopharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/ARGRXRegeneRx Biopharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableRGRXRegeneRx Biopharmaceuticals31.51 million1.32 millionNot OptionableRGRX, ATNFW, LBPSW, and FFNTF HeadlinesRecent News About These CompaniesEIGRQ Eiger BioPharmaceuticals, Inc.July 19, 2024 | seekingalpha.comThe Hawryluk Biopharmaceutical ScholarsJanuary 1, 2024 | kellogg.northwestern.eduRegenerx Biopharmaceuticals Inc RGRXDNovember 5, 2023 | morningstar.comRegenerx Biopharm In (RGRXD)October 31, 2023 | investing.comLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater ChinaSeptember 21, 2023 | businesswire.comJeannette company becomes leader in recycling biopharmaceutical wasteSeptember 18, 2023 | triblive.comRGRX RegeneRx Biopharmaceuticals, Inc.August 26, 2023 | seekingalpha.comRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting ObligationsAugust 15, 2023 | finance.yahoo.comRegeneRx Receives Stockholder Approval for Reverse Stock SplitAugust 8, 2023 | finance.yahoo.comRegeneRx To Extend Consent Solicitation VoteAugust 1, 2023 | finance.yahoo.comBristol-Myers to Split Off Mead JohnsonJuly 7, 2023 | thestreet.comPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage InitiationMay 19, 2023 | thestreet.comFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259April 13, 2023 | finance.yahoo.comBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030April 7, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029April 7, 2023 | marketwatch.comCURIA, CORNING BOOST BIOPHARMACEUTICAL CONTINUOUS-FLOW DEVELOPMENT, MANUFACTURINGApril 4, 2023 | bernama.com2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029March 1, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 24, 2023 | marketwatch.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)February 12, 2023 | finance.yahoo.comMedia Sentiment Over TimeRGRX, ATNFW, LBPSW, and FFNTF Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.0083 0.00 (-1.19%) As of 06/24/2025 03:56 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4Front Ventures OTCMKTS:FFNTF$0.0002 +0.00 (+100.00%) As of 06/24/2025 02:33 PM Eastern4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.RegeneRx Biopharmaceuticals OTCMKTS:RGRX$0.0002 0.00 (0.00%) As of 06/20/2025RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
